Publications by authors named "Keri Yang"

Claim this Profile
Z
Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma.
Bijal Shah, Swetha Challagulla, Sheng Xu, Rhys Williams, Shijie Ren, Keri Yang

Leuk Lymphoma· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indirect Comparisons of the Efficacy and Safety of Zanubrutinib versus Venetoclax plus Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Talha Munir, Nicolás Martinez-Calle, Sheng Xu, Keri Yang, Xiaoyun Ge

Oncol Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidemiology, Real-World Treatment, and Economic Burden of Waldenström Macroglobulinemia: A Comprehensive Analysis Based on Anonymized Claims Data Between 2010 and 2022.
Christian Buske, Michael Herold, Nasim Bahar, Keri Yang, Boxiong Tang

Value Health Reg Issues· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matching-adjusted indirect comparisons of efficacy and safety for zanubrutinib versus the combination of fixed-duration venetoclax and ibrutinib in patients with treatment-naïve chronic lymphocytic leukaemia.
Talha Munir, Leyla Mohseninejad, Pal Rakonczai, Balazs Dobi, Sheng Xu, Keri Yang

Br J Haematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia.
Vincent Lévy, Tushar Srivastava, Raju Gautam, Shilpi Swami, Kaijun Wang, Keri Yang

Leuk Lymphoma· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting.
Bijal D Shah, Mei Xue, Wesley Furnback, Keri Yang

Future Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Systematic Literature Review of the Economic and Healthcare Resource Utilization Burden of Relapsed/Refractory Follicular Lymphoma.
Bijal Shah, Mei Xue, Wesley Furnback, Erlene K Seymour, Jin Kim, Keri Yang

Pharmacoecon Open· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of zanubrutinib versus acalabrutinib for relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC).
Mazyar Shadman, Jennifer R Brown, Rhys Williams, Leyla Mohseninejad, Keri Yang

Ther Adv Med Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis.
Mazyar Shadman, Jennifer R Brown, Leyla Mohseninejad, Keri Yang, Heather Burnett

Blood Adv· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Number needed to treat and associated cost analysis of zanubrutinib vs ibrutinib in chronic lymphocytic leukemia.
Asher Chanan-Khan, Kirollos Hanna, Mei Xue, Marjan Massoudi, Mark Balk, Keri Yang

J Manag Care Spec Pharm· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated health system pharmacy role in adherence, persistence, and adverse effect management for oral chronic lymphocytic leukemia therapy.
Houston Wyatt, Stephanie White, Hannah Holloway, Josh DeClercq, Autumn D Zuckerman, Keri Yang

J Manag Care Spec Pharm· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matching-adjusted indirect comparisons of zanubrutinib (MAGNOLIA, BGB-3111-AU-003) versus ibrutinib (PCYC-1121) and rituximab (CHRONOS-3) in relapsed/refractory marginal zone lymphoma.
Catherine Thieblemont, Björn E Wahlin, Leyla Mohseninejad, Kaijun Wang, Ina Zhang, Keri Yang

Leuk Lymphoma· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial.
Alessandra Tedeschi, Constantine S Tam, Roger G Owen, Christian Buske, Véronique Leblond, Keri Yang

Future Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disparity in treatment patterns among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia: an analysis of patient and contextual factors.
Jean A Yared, Tsung-Ying Lee, Catherine E Cooke, Abree Johnson, Amanda Summers, Keri Yang

Leuk Lymphoma· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison.
Mazyar Shadman, Alessandra Tedeschi, Leyla Mohseninejad, Keri Yang, Nicole Lamanna

Blood Cancer J· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Costs and health care resource utilization among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia.
Tsung-Ying Lee, Abree Johnson, Catherine E Cooke, Jean A Yared, Amanda Summers, Keri Yang

J Manag Care Spec Pharm· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of atrial fibrillation in onco-hematological patients in Europe: a targeted literature review.
Fernando Escalante Barrigón, Cristina Bas, Boxiong Tang, Keri Yang, Elisenda Pomares

Expert Rev Hematol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality-of-life in treatment-naive CLL/SLL patients treated with zanubrutinib versus bendamustine plus rituximab.
Paolo Ghia, Gisoo Barnes, Keri Yang, Constantine S Tam, Tadeusz Robak

Curr Med Res Opin· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life outcomes associated with zanubrutinib versus ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from the ALPINE Trial.
Constantine S Tam, Nicole Lamanna, Susan M O'Brien, Lugui Qiu, Keri Yang

Curr Med Res Opin· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States.
Anthony Mato, Boxiong Tang, Soraya Azmi, Keri Yang, Yi Han

EJHaem· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib.
Anthony R Mato, Boxiong Tang, Soraya Azmi, Keri Yang, Xiaojuan Zhang

Haematologica· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of PD-1 and PD-L1 inhibitors after first-line therapy in esophageal cancer patients in the US.
Jason C Allaire, Mark Balk, Soraya Azmi, Heather L Handl, Keri Yang

Curr Med Res Opin· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of intraoperative dosing patterns of neuromuscular blocking agents.
Sarah Palsen, Albert Wu, Sascha S Beutler, Robert Gimlich, H Keri Yang

J Clin Monit Comput· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Healthcare Use and Clinical Outcomes of Alvimopan in Patients Undergoing Bowel Resection: A Propensity Score-Matched Analysis.
Scott R Steele, Justin T Brady, Zhun Cao, Dorothy L Baumer, Scott B Robinson, H Keri Yang

Dis Colon Rectum· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of high- versus low-dose neuromuscular blocking agent administration on unplanned 30-day readmission rates in retroperitoneal laparoscopic surgery.
Martijn Boon, Chris Martini, H Keri Yang, Shuvayu S Sen, Rob Bevers

PLoS One· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis